This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458508098268v1 15/2/189    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petereit, H. Articles by Rubbert-Roth, A Search for Related Content PubMed PubMed Citation Articles by Petereit, H. Articles by Rubbert-Roth, A Social Bookmarking                         What's this?

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

¹ Department of Neurology, Heilig Geist-Krankenhaus, Köln, Germany
² Department of Internal Medicine I, University of Cologne, Köln, Germany

^* To whom correspondence should be addressed.

	Abstract

Background

Rituximab, a monoclonal antibody against the B-cell-specific surface protein CD20, is being evaluated for treatment of multiple sclerosis and neuromyelitis optica. Both diseases are restricted to the brain and cerebrospinal fluid (CSF). Whereas the ability of rituximab to deplete B cells in peripheral blood and tissue is well known, little information is available about the ability of rituximab to penetrate the barriers separating brain and CSF from the serum compartment.

Objective

To measure rituximab levels in serum and CSF of rituximab-treated patients and correlate them with CSF and response markers.

Methods

Fourteen paired serum/CSF samples of patients with autoimmune nervous system disorder were analyzed for up to 43 weeks after rituximab application.

Results

Rituximab remains detectable within the CSF after i.v. application for up to 24 weeks. Furthermore, levels of rituximab in CSF correlate significantly with the integrity of the blood CSF barrier.

Key Words: blood-CSF-barrier, intrathecal Ig synthesis, multiple sclerosis, rituximab

First published on October 29, 2008, doi:10.1177/1352458508098268

Multiple Sclerosis 2009;15:189.

A more recent version of this article appeared on February 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?